COMP <GO>
ELAN vs ABBV // RSI-14 & 200D SMA MOMENTUM
Elanco Animal Health Incorporated (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ELAN 2
— ABBV 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $23.06 (-0.77%) • MKT CAP: $11.61B
rsi-technicals
52.5
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELAN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELAN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.00% | 70.20% | -15.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | 29.00% | -31.50 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 3.47% | -1.02 | ABBV | /fcf-yield <GO> |
| Operating Margin | -6.00% | 24.60% | -30.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -4.90% | 6.90% | -11.80 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.20% | 8.60% | -2.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.24 | 5.33 | -4.09 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | ELAN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 52.5 | 72.8 | -20.32 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.15 | -0.19 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 113.1x | -93.10 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.61B | $513.86B | -$502.25B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELAN REV | ABBV REV | ELAN GROSS % | ABBV GROSS % | ELAN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.71B | $61.16B | 55.0% | 70.2% | $284.0M | $17.82B |
| FY 2024 | $4.44B | $56.33B | 54.9% | 70.0% | $394.0M | $17.83B |
| FY 2023 | $4.42B | $54.32B | 44.0% | 44.0% | $72.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELAN // BETA 0.96
ABBV // BETA 1.15